EGFR and metastatic colorectal cancer: Several clinical trials have explored the use of cetuximab or panitumumab monoclonal antibodies (mAbs) to target the Epidermal Growth Factor Receptor (EGFR) in the treatment of RAS wild type (WT) metastatic colorectal cancer (mCRC) among different lines of treatment (3).